First Financial Bank Trust Division grew its position in Eli Lilly and Company (NYSE:LLY) by 11.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,705 shares of the company’s stock after buying an additional 578 shares during the quarter. First Financial Bank Trust Division’s holdings in Eli Lilly and were worth $469,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Heritage Trust Co purchased a new position in shares of Eli Lilly and in the first quarter valued at $135,000. Point72 Asia Hong Kong Ltd increased its position in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Penserra Capital Management LLC increased its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares in the last quarter. American National Bank increased its position in shares of Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock valued at $172,000 after buying an additional 104 shares in the last quarter. Finally, Sandy Spring Bank increased its position in shares of Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock valued at $185,000 after buying an additional 750 shares in the last quarter. Institutional investors and hedge funds own 75.72% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/eli-lilly-and-company-lly-shares-bought-by-first-financial-bank-trust-division/1578601.html.

LLY has been the subject of a number of research analyst reports. Jefferies Group LLC restated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, May 30th. TheStreet cut Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. BidaskClub upgraded Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Zacks Investment Research cut Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. Finally, Barclays PLC raised their price target on Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, July 4th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and an average target price of $88.27.

In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the transaction, the insider now directly owns 123,682,287 shares of the company’s stock, valued at $10,207,499,146.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 590,000 shares of company stock worth $48,551,300 over the last three months. 0.20% of the stock is owned by insiders.

Shares of Eli Lilly and Company (NYSE LLY) traded up 1.58% during mid-day trading on Thursday, reaching $83.32. The company’s stock had a trading volume of 1,790,043 shares. The company has a market capitalization of $87.90 billion, a PE ratio of 36.05 and a beta of 0.34. The firm’s 50 day moving average is $80.84 and its 200-day moving average is $82.02. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.86 earnings per share. Analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.